Sanofi Underpins Vaccine Strategy With New Manufacturing Facilities
Sanofi's major investments in vaccine manufacturing are continuing with the expansion of its Toronto, Canada facility, to be completed in 2021.
You may also be interested in...
A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.